Exogenus Leads €13M EU Consortium to Pioneer Osteoarthritis Secretome Therapy

CANTANHEDE, Portugal – October 29, 2026 — The race to fundamentally alter the trajectory of osteoarthritis has long been a graveyard for single-target pharmaceuticals. Today, a Portuguese biotechnology company is betting that the solution lies not in a single molecule, but in the complex, multifactorial signaling of human secretomes. Exogenus Therapeutics has officially launched ExoCordOA, a five-year, €13 million initiative funded by the European Union’s Horizon Europe program.

Under Grant Agreement No. 101288259, the consortium unites ten formidable organizations—spanning biomanufacturing, regulatory affairs, and clinical research—to advance EXO-101, a novel biologic candidate, through Phase I and II clinical trials. But the ambition of ExoCordOA extends far beyond a single asset. By bringing together heavyweights like Lonza and Eliquent Life Sciences, the project aims to dismantle the systemic manufacturing and regulatory bottlenecks that have historically paralyzed the extracellular vesicle (EV) and secretome therapeutics industry.

“ExoCordOA brings together the expertise needed not only to advance EXO-101 towards clinical validation in osteoarthritis, but also to tackle barriers affecting the wider secretome therapeutics field,” said Joana Correia, PhD, Co-Founder and Chief Executive Officer of Exogenus Therapeutics. “As project coordinator, Exogenus is proud to lead this collaborative European effort to establish stronger scientific, manufacturing and regulatory foundations for a new generation of regenerative medicines.”

The Quest for the First DMOAD: Can Secretome Therapies Stop Osteoarthritis Progression?

Osteoarthritis (OA) is a leading cause of global disability, affecting approximately eight percent of the world’s population. As demographics skew older, the economic and human toll of the disease is accelerating. Yet, the therapeutic landscape remains remarkably primitive. There are currently zero approved disease-modifying osteoarthritis drugs (DMOADs) on the market. Patients are routinely relegated to a grim pipeline of temporary symptom management—NSAIDs and corticosteroid injections—culminating inevitably in invasive joint replacement surgery.

The pharmaceutical industry’s historical approach to DMOADs has been fraught with high-profile clinical failures. Regulatory agencies like the FDA and EMA demand that a true DMOAD demonstrate both symptomatic relief and structural joint modification, such as halting the loss of joint space width. While pipeline candidates are currently navigating late-stage trials—including lorecivivint, a small-molecule inhibitor modulating Wnt pathways, and sprifermin, a recombinant protein aimed at inducing cartilage growth—the complex, heterogeneous nature of OA has consistently thwarted single-target interventions. Even novel gene therapies like BBM-A101 are entering the fray, yet a definitive market leader has yet to emerge.

This is where EXO-101 diverges from its predecessors. Derived from native, non-engineered umbilical cord blood cells, EXO-101 is an extracellular vesicle-enriched secretome. Rather than targeting a single inflammatory receptor, it deploys a sophisticated cocktail of bioactive proteins, microRNAs, and lipids designed to act across multiple disease pathways simultaneously.

Preclinical data suggests that EXO-101 operates largely through immune cell modulation. By "nudging" macrophages toward an anti-inflammatory phenotype, the therapy aims to interrupt the chronic inflammatory loop that drives cartilage degradation. Rooted in earlier research demonstrating accelerated wound healing and tissue repair, this multifactorial mechanism offers a compelling biological rationale for OA. If successful in its first-in-human Phase 1b trials—slated for early 2028 in patients with moderate osteoarthritis—EXO-101 could establish a new paradigm for joint preservation.

Building Europe's Blueprint for Extracellular Vesicle Regulation and Manufacturing

While the biological promise of extracellular vesicles is immense, the commercial reality has been stifled by severe bioprocessing and regulatory hurdles. The translation of EV-based products from academic laboratories into commercial therapies is notoriously difficult. The industry suffers from a lack of standardized isolation methods, making batch-to-batch consistency a persistent nightmare. Achieving high yields of specific EV subpopulations while simultaneously removing host cell proteins, rogue DNA, and optimizing cell culture media for bioreactors requires a level of bioprocessing finesse that few early-stage biotechs possess.

For a therapy to reach the market, developers must prove to regulators that they can maintain product integrity at a commercial scale. Furthermore, the regulatory pathways themselves remain opaque, as agencies struggle to define standardized metrics for dosage complexity, such as particle counts and surface marker expression.

The ExoCordOA consortium is explicitly designed to solve this infrastructure deficit. By integrating Lonza, a global contract development and manufacturing organization (CDMO) with over a decade of dedicated EV experience, the project brings industrial-scale bioprocessing expertise to the table. Lonza’s EV Center of Excellence in Siena, Italy, provides the advanced capabilities necessary to transition EXO-101 from a promising benchtop biologic into a scalable, GMP-compliant medicine.

"The challenge with secretomes isn't just proving they work in mice; it's proving you can manufacture a million vials that are identical in purity and potency," noted one bioprocessing engineer familiar with the consortium's goals. "Partnering with a CDMO that already understands the nuances of EV isolation and characterization is the only way to survive the clinical translation phase."

Parallel to manufacturing, Eliquent Life Sciences will navigate the regulatory labyrinth. The consulting firm is tasked with translating the latest International Society for Extracellular Vesicles (ISEV) guidelines—such as MISEV2023—into actionable regulatory strategies. By establishing robust analytical and potency-assessment methods, ExoCordOA hopes to draft a definitive blueprint that the EMA and FDA can adopt for future secretome-based medicines.

Public Funding, Private Innovation: How Horizon Europe is De-Risking Early Regenerative Medicine

The launch of ExoCordOA underscores a critical dynamic in the modern biotechnology ecosystem: the indispensable role of non-dilutive public capital in de-risking advanced therapies. The European Commission’s €13 million Horizon Europe grant is not merely a financial lifeline for Exogenus Therapeutics; it is a strategic maneuver by the EU to secure sovereign leadership in the next generation of regenerative medicine.

Venture capital is historically risk-averse when it comes to novel modalities lacking established regulatory precedents. By injecting substantial public funds into the ExoCordOA project, Horizon Europe bridges the "valley of death" that frequently claims early-stage biologics. This funding allows Exogenus to aggressively pursue Phase I and II clinical validation without prematurely diluting equity or abandoning the asset due to capital constraints.

The consortium's structure—blending agile biotech innovators like Exogenus and iLoF, industrial scale from Lonza, academic rigor from Utrecht University and Maastricht UMC+, and patient advocacy from ReumaNederland—creates a holistic ecosystem optimized for clinical success. It represents a sophisticated model of public-private partnership where the financial risk is socialized, but the technological and therapeutic upside remains squarely within the European innovation economy.

Beyond osteoarthritis, the infrastructure funded by this grant will pay dividends across Exogenus’s broader pipeline. The company is already investigating EXO-101 for platinum-chemotherapy-induced hearing loss (EXO-OTOProtect), as well as lung and other organ fibroses. By standardizing the manufacturing and regulatory frameworks for secretome therapies today, the ExoCordOA consortium is laying the tracks for a massive expansion of regenerative applications tomorrow. The success of this €13 million gamble will ultimately be measured not just by the fate of EXO-101, but by whether Europe can dictate the global standards for the therapies of the future.